分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Apoptotic BMSCs reduce grafted islets apoptosis through the holo-Lcn2/Slc22a17/Fe3+ axis

Lu Cuinan, Wang Jiale, Wang Ying, Wang Jingwen, Bi Huanjing, Yu Xiaoyang, Chen Zuhan, Dong Boqing, Ma Ruiyang, Ding Xiaoming

Journal:Stem Cell Research & Therapy

IF:7.8

DOI:10.1186/s13287-026-05001-9

PMID:

Published:2026-04-10

research field:内分泌学细胞生物学再生医学移植生物学

Abstract

Early apoptosis of grafted islets is one of the critical challenges that significantly impact the efficacy of islet transplantation. We employed Staurosporine to pre-induce apoptosis in bone marrow mesenchymal stem cells (BMSCs). The conditioned medium from apoptotic BMSCs was then used to pretreat β cells, which notably enhanced the suppression of β cell apoptosis. For in vivo experiments, co-transplantation of islets and apoptotic BMSCs under the renal capsule of diabetic rats inhibited islets apoptosis and resulted in better transplantation outcomes. Subsequently proteomic analysis revealed that the iron-loaded form of Lcn2 protein (holo-Lcn2) secreted by apoptotic BMSCs played a crucial role in exerting anti-apoptotic effects. Holo-Lcn2 binds to the Slc22a17 transporter on cell membrane, facilitating the transport of Fe3+ into cells. Inhibition of Fe3+ transport suppressed the anti-apoptotic effect of holo-Lcn2. Thus, we hypothesize that apoptotic BMSCs reduce grafted islets apoptosis through the holo-Lcn2/Slc22a17/Fe3+ axis. This study provides insights into the application of BMSCs-based acellular therapies in islet transplantation.

本文使用的Yeasen产品

购物车
客服
转染试用